Global cross-sectional burden-of-illness study in adolescent and adult patients with atopic dermatitis (MEASURE-AD)

• Conditions: L20-L30; Dermatitis and eczema

• Registration Number: DRKS00019854
• Lead Sponsor: AbbVie Deutschland GmbH & Co. KG

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-01-21
• Study Completion: 2020-11-24
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 1593

Inclusion Criteria

• physician confirmed diagnosis of atopic dermatitis
• moderate to severe AD patients who are (i) current candidates for systemic therapy for AD according to the HCP, or (ii) currently receiving systemic therapy for AD.
• medication history available within the last 6 months
• able to understand the questionnaires, with parental support as required for adolescents
• willing to provide a patient authorization form to use and disclose personal health information (or informed consent, where applicable) to participate in the study; for adolescent subjects, authorization and/or consent will be provided by a parent or legal guardian, where applicable

Exclusion Criteria

Patients will be excluded if currently participating in interventional clinical trial(s). Participation in another non-interventional study or registry does not exclude a patient from this study.

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To characterize the multidimensional burden of disease in adolescent and adult patients with moderate to severe AD with single data collection

Secondary Outcome Measures

Name	Time	Method
• To describe the patient characteristics, current local treatment patterns and the treatment history of moderate to severe AD patients in dermatology offices and clinics.<br>• To characterize disease burden related to pain, sleep and mental health in patients with moderate to severe AD.<br>• To evaluate work productivity and out of pocket costs for AD patients<br>• To characterize health care resource utilization.<br>• To assess the impact of chronic comorbidities on disease burden.<br>• To evaluate the frequency and characteristics of patients with inadequately controlled disease receiving different treatments.<br>• To evaluate the frequency and characteristics of patients who experience AD flare.